Semaglutide vs. Tirzepatide: Which One Is Right for Your Patient?

The clinical evidence on semaglutide versus tirzepatide is no longer ambiguous. Tirzepatide produces greater weight loss. The SURMOUNT-1 trial showed 20.9% body weight reduction at 15 mg versus semaglutide’s 15–17% in STEP — a gap that has held across subsequent trials.

But “which drug wins in trials” is not the same question as “which drug is right for this patient.” The trial data is the starting point. Here’s the prescribing framework for 2026.

---

The Core Mechanistic Difference

Semaglutide is a GLP-1 receptor agonist. It mimics endogenous GLP-1 — slowing gastric emptying, stimulating insulin secretion, and acting on hypothalamic satiety pathways. Once-weekly subcutaneous injection (Wegovy for obesity; Ozempic for T2D) or daily oral (Rybelsus).

Tirzepatide adds GIP receptor agonism to GLP-1 agonism. GIP receptors are expressed in adipose tissue, and the combination appears synergistic — not merely additive. GIP co-agonism is the likely explanation for tirzepatide’s superior efficacy in weight reduction. Once-weekly subcutaneous injection (Zepbound for obesity; Mounjaro for T2D).

The practical implication: tirzepatide’s advantage is largest in patients with significant adiposity and relatively intact GIP receptor signaling. It doesn’t universally outperform semaglutide in every patient — that’s a trial average, not a biological constant.

---

Weight Loss Comparison

Trial	Drug	Dose	Weight Loss
STEP 1	Semaglutide	2.4 mg/wk	14.9%
STEP 5 (2-year)	Semaglutide	2.4 mg/wk	15.2%
SURMOUNT-1	Tirzepatide	10 mg/wk	19.5%
SURMOUNT-1	Tirzepatide	15 mg/wk	20.9%
SURMOUNT-3 (intensive lifestyle)	Tirzepatide	15 mg/wk	24.3%

The SURMOUNT-3 number — nearly 25% body weight reduction — is the highest ever recorded in an obesity pharmacotherapy trial. For context, bariatric surgery typically produces 25–35% loss. Tirzepatide at maximal dose with lifestyle support is approaching surgical territory in some patients.

---

Cardiovascular Outcomes: Semaglutide Has the Data

This is where semaglutide currently has a meaningful advantage.

SELECT trial (semaglutide): 17,604 non-diabetic overweight patients with prior cardiovascular disease. Semaglutide 2.4 mg weekly reduced MACE (heart attack, stroke, CV death) by 20% over 3.3 years. This is a landmark finding — it established that cardiovascular benefit is independent of T2D status.

Tirzepatide cardiovascular data: The SURPASS-CVOT trial is ongoing and results are expected in 2026. Tirzepatide has robust indirect cardiovascular markers (weight, lipids, blood pressure, HbA1c) but no completed outcomes trial yet.

Prescribing implication: For a patient with established ASCVD or high cardiovascular risk who is not primarily weight-focused, semaglutide’s SELECT data makes it the evidence-backed choice today. That calculus may shift when SURPASS-CVOT reports.

---

Tolerability: Similar Profiles, Meaningful Differences

Both drugs share a GI side effect profile — nausea, vomiting, diarrhea — that is most prominent during dose titration and typically improves over weeks.

Discontinuation rates:

• Semaglutide (STEP 1): ~7% due to adverse events
• Tirzepatide (SURMOUNT-1): ~4.3% due to adverse events

Tirzepatide’s lower discontinuation rate despite higher efficacy is notable. It may reflect better tolerability at therapeutic doses, the GIP component modulating GI effects, or simply better titration protocols in more recent trials.

Nausea specifically:

• Semaglutide: nausea in ~44% during escalation
• Tirzepatide: nausea in ~30–33% at therapeutic doses

For GI-sensitive patients, tirzepatide may paradoxically be the better-tolerated option at equivalent efficacy doses. This runs counter to the assumption that the “stronger” drug is harder to tolerate.

Pancreatitis and thyroid concerns: Both carry class labeling for pancreatitis risk (low absolute risk) and thyroid C-cell tumor risk (based on rodent data; human signal not established). Neither should be prescribed to patients with personal or family history of medullary thyroid carcinoma or MEN2.

---

Who Gets Semaglutide

• Established ASCVD or high CV risk where SELECT data matters now
• Patients who prefer oral administration (Rybelsus — lower efficacy than SC, but oral)
• Patients with insurance coverage for Ozempic when Wegovy isn’t covered
• Prior non-response to tirzepatide (receptor mechanism difference may matter)
• Cost-constrained patients where generic semaglutide compounding was accessible — note this is now legally prohibited following shortage resolution

---

Who Gets Tirzepatide

• Patients whose primary goal is maximum weight loss
• Class 3 obesity (BMI ≥40), where the incremental 5–6% weight loss vs. semaglutide is clinically significant
• T2D patients — Mounjaro has superior HbA1c reduction data vs. semaglutide in the SURPASS vs. STEP comparisons
• Patients who failed or plateaued on semaglutide
• Patients concerned about GI side effects — counterintuitive but data-supported
• Younger patients without established CVD where cardiovascular outcomes data gap is less relevant

---

Access and Cost in 2026

Both drugs remain expensive without insurance. List prices run $900–$1,400/month. Coverage has expanded as obesity gains recognition as a disease state, but prior authorization hurdles remain significant.

Compounding: The FDA removed both semaglutide and tirzepatide from drug shortage lists in late 2024. Compounded versions are no longer legally available through 503A pharmacies. Enforcement has been active. Patients sourcing compounded versions are taking legal and safety risk that practitioners should document and counsel against.

Manufacturer savings programs:

• Novo Nordisk (semaglutide): Wegovy savings card, insulin assistance programs
• Eli Lilly (tirzepatide): Zepbound savings program, LillyDirect direct-to-patient pharmacy

---

The Bottom Line

Tirzepatide is the more effective drug on average. Semaglutide has the more complete cardiovascular outcomes record. For most patients presenting with obesity as the primary concern, absent significant CV history, tirzepatide at 10–15 mg is the current evidence-backed choice.

For patients with established ASCVD, the SELECT trial makes semaglutide a defensible first-line until SURPASS-CVOT reports. When that data publishes, the calculus will likely shift entirely to tirzepatide.

Neither drug is a one-size answer. The mechanism differences are real, individual response varies, and the right choice still depends on the patient in front of you.

→ Semaglutide monograph | Tirzepatide monograph | Retatrutide: What comes next